

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

HERON THERAPEUTICS, INC.,

Plaintiff,

v.

FRESENIUS KABI USA, LLC,

Defendant.

C.A. No. 22-985-WCB

STIPULATION AND [PROPOSED] ORDER DISMISSING CERTAIN PATENTS

Pursuant to Federal Rule of Civil Procedure 41, Plaintiff Heron Therapeutics, Inc. (“Heron”) and Defendant Fresenius Kabi USA, LLC (“Fresenius”) hereby stipulate as follows:

WHEREAS, Heron sued Fresenius in this action (“Action”) for infringement under 35 U.S.C. § 271(e)(2) of, *inter alia*, U.S. Patent Nos. 9,808,465 (“the ’465 patent”); 9,973,793 (“the ’793 patent”); 10,500,208 (“the ’208 patent”); and 10,953,018 (“the ’018 patent”), based on Fresenius’s submission to the United States Food and Drug Administration of Abbreviated New Drug Application (“ANDA”) No. 214639 seeking approval to engage in the commercial manufacture, use, sale, or offer for sale of an injectable emulsion containing 130 mg/18 mL (7.2 mg/mL) aprepitant as described in said ANDA (“Fresenius’s ANDA Product”);

WHEREAS, Fresenius filed counterclaims in this Action for noninfringement and invalidity of the ’465 patent, the ’793 patent, the ’208 patent, and the ’018 patent; and the parties have completed their written discovery responses and document productions;

NOW THEREFORE, Heron and Fresenius, by their undersigned counsel, and subject to the approval of the Court, STIPULATE as follows:

1. Pursuant to Federal Rule of Civil Procedure 41(a)(2), Heron hereby dismisses without prejudice its claims that Fresenius's ANDA Product infringes any claims of the '465 patent, the '793 patent, the '208 patent, and the '018 patent under 35 U.S.C. § 271(e)(2).

2. Pursuant to Federal Rule of Civil Procedure 41(a)(2) and 41(c), Fresenius hereby dismisses without prejudice its counterclaims against all claims of the '465 patent, the '793 patent, the '208 patent, and the '018 patent.

3. All claims asserted by Heron with respect to patents other than the '465 patent, the '793 patent, the '208 patent, and the '018 patent, and those dismissed by prior Order entered in this case (D.I. 40), shall continue in this Action. For the avoidance of doubt, this Order shall not dismiss any claims from U.S. Patent Nos. 9,561,229 or 9,974,794.

4. Each party shall bear its own costs, expenses, and attorneys' fees incurred in connection with the claims dismissed by this Order.

5. The Court retains jurisdiction over the parties to this Action for purposes of enforcing this Stipulation and Order.

6. This Stipulation and Order shall not act as an adjudication on the merits.

Dated: March 8, 2024

SO STIPULATED:

/s/ Jeremy A. Tigan

Jack B. Blumenfeld (#1014)
Jeremy A. Tigan (#5239)
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
jtigan@morrisnichols.com

OF COUNSEL:

Bruce M. Wexler
Isaac S. Ashkenazi
Christopher P. Hill
Mark Russell Sperling
Justin T. Fleischacker
PAUL HASTINGS LLP
200 Park Avenue
New York, NY 10166
(212) 318-6000

*Attorneys for Plaintiff
Heron Therapeutics, Inc.*

/s/ Daniel A. Taylor

Neal C. Belgam (No. 2721)
Daniel A. Taylor (No. 6934)
SMITH, KATZENSTEIN & JENKINS LLP
1000 West Street, Suite 1501
Wilmington, DE 19801
(302) 652-8400
nbelgam@skjlaw.com
dtaylor@skjlaw.com

OF COUNSEL:

Imron T. Aly
Kevin M. Nelson
Helen H. Ji
Julie A. Vernon
ARENTFOX SCHIFF LLP
233 South Wacker Drive, Suite 7100
Chicago, IL 60606
(312) 258-5500
Imron.Aly@afslaw.com
Kevin.Nelson@afslaw.com
Helen.Ji@afslaw.com
Julie.Vernon@afslaw.com

*Attorneys for Defendant
Fresenius Kabi USA, LLC*

SO ORDERED this ___ day of March, 2024.

WILLIAM C. BRYSON
UNITED STATES CIRCUIT JUDGE